How to buy IQVIA stock | $168.5

IQVIA Holdings Inc is a diagnostics & research business based in the US. IQVIA shares (IQV) are listed on the NYSE and all prices are listed in US Dollars. IQVIA employs 68,000 staff and has a trailing 12-month revenue of around USD$11 billion.

How to buy shares in IQVIA

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for IQVIA. Find the stock by name or ticker symbol: IQV. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until IQVIA reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$168.5, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of IQVIA, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of IQVIA. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

IQVIA share price

Use our graph to track the performance of IQV stocks over time.

IQVIA shares at a glance

• Key figures

Information last updated 2020-12-27.

Latest market close	USD$168.5
52-week range	USD$81.79 - USD$180.99
50-day moving average	USD$171.4677
200-day moving average	USD$159.5682
Wall St. target price	USD$199.89
PE ratio	194.1943
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$0.906

Buy IQVIA shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy IQVIA stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of IQVIA Holdings Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

IQVIA price performance over time

Historical closes compared with the close of $168.5 from 2020-12-09

1 week (2021-01-12)	-11.04%
1 month (2020-12-18)	-6.59%
3 months (2020-10-19)	2.71%
6 months (2020-07-17)	9.38%

1 year (2020-01-17)	4.33%
2 years (2019-01-18)	32.48%
3 years (2018-01-19)	63.59%
5 years (2016-01-19)	165.94%

Is IQVIA under- or over-valued?

Valuing IQVIA stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of IQVIA's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

IQVIA's P/E ratio

IQVIA's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 194x. In other words, IQVIA shares trade at around 194x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

IQVIA's PEG ratio

IQVIA's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.2389. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into IQVIA's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

IQVIA's EBITDA

IQVIA's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$1.8 billion.

The EBITDA is a measure of a IQVIA's overall financial performance and is widely used to measure a its profitability.

IQVIA financials

Revenue TTM	USD$11 billion
Operating margin TTM	6.49%
Gross profit TTM	USD$3.8 billion
Return on assets TTM	1.9%
Return on equity TTM	3.17%
Profit margin	1.61%
Book value	$30.496
Market capitalisation	USD$33.7 billion

TTM: trailing 12 months

Shorting IQVIA shares

There are currently 2.0 million IQVIA shares held short by investors – that's known as IQVIA's "short interest". This figure is 1.3% up from 1.9 million last month.

There are a few different ways that this level of interest in shorting IQVIA shares can be evaluated.

IQVIA's "short interest ratio" (SIR)

IQVIA's "short interest ratio" (SIR) is the quantity of IQVIA shares currently shorted divided by the average quantity of IQVIA shares traded daily (recently around 1.1 million). IQVIA's SIR currently stands at 1.83. In other words for every 100,000 IQVIA shares traded daily on the market, roughly 1830 shares are currently held short.

However IQVIA's short interest can also be evaluated against the total number of IQVIA shares, or, against the total number of tradable IQVIA shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case IQVIA's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 IQVIA shares in existence, roughly 10 shares are currently held short) or 0.0114% of the tradable shares (for every 100,000 tradable IQVIA shares, roughly 11 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against IQVIA.

Find out more about how you can short IQVIA stock.

IQVIA's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like IQVIA.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

IQVIA's total ESG risk score

Total ESG risk: 26.81

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and IQVIA's overall score of 26.81 (as at 01/01/2019) is pretty good – landing it in it in the 37th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like IQVIA is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

IQVIA's environmental score

Environmental score: 1.17/100

IQVIA's environmental score of 1.17 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that IQVIA is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

IQVIA's social score

Social score: 14.76/100

IQVIA's social score of 14.76 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that IQVIA is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

IQVIA's governance score

Governance score: 6.88/100

IQVIA's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that IQVIA is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

IQVIA's controversy score

Controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. IQVIA scored a 1 out of 5 for controversy – the highest score possible, reflecting that IQVIA has managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

IQVIA Holdings Inc was last rated for ESG on: 2019-01-01.

Total ESG score	26.81
Total ESG percentile	36.72
Environmental score	1.17
Environmental score percentile	3
Social score	14.76
Social score percentile	3
Governance score	6.88
Governance score percentile	3
Level of controversy	1

IQVIA share dividends

We're not expecting IQVIA to pay a dividend over the next 12 months.

IQVIA share price volatility

Over the last 12 months, IQVIA's shares have ranged in value from as little as $81.79 up to $180.99. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while IQVIA's is 1.4. This would suggest that IQVIA's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

IQVIA overview

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support services; and strategic planning and design services, as well as clinical trial, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company has a strategic alliance with ACCORD-2 to provide single research platform to speed development of new COVID-19 treatments. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

Frequently asked questions

• What percentage of IQVIA is owned by insiders or institutions?

  Currently 0.737% of IQVIA shares are held by insiders and 92.13% by institutions.

• How many people work for IQVIA?

  Latest data suggests 68,000 work at IQVIA.

• When does the fiscal year end for IQVIA?

  IQVIA's fiscal year ends in December.

• Where is IQVIA based?

  IQVIA's address is: 4820 Emperor Boulevard, Durham, NC, United States, 27703

• What is IQVIA's ISIN number?

  IQVIA's international securities identification number is: US46266C1053

• What is IQVIA's CUSIP number?

  IQVIA's Committee on Uniform Securities Identification Procedures number is: 46266C105